EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

• Status: Completed
• Trial end date: 2019-05-20
• Target enrollment: 0
• Participant gender: All

Summary

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).

The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice.

A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Patients who received EYLEA for AMD

Exclusion Criteria:

• Patients who have already received EYLEA